Singapore Company Guide

Singapore Exchange

Version 15 | Bloomberg: SGX SP | Reuters: SGXL.SI

Refer to important disclosures at the end of this report

DBS Group Research . Equity

HOLD (downgrade from BUY)

Last Traded Price (24 Apr 2020): S\$9.64 (**STI :** 2,518.16) **Price Target 12-mth:** S\$10.00 (4% upside) (Prev S\$9.60)

Analyst

Rui Wen LIM +65 66823720 ruiwenlim@dbs.com

What's New

- Net profit of S\$138m (+38%y-o-y) beat consensus estimates
- 3QFY20 saw strong revenue growth across all segments
- Interim dividend of 7.5 Scts declared (unchanged y-o-y)
- Downgrade to HOLD, with revised TP of S\$10, on rich near-term valuations



Forecasts and Valuation				
FY Jun (S\$m)	2019A	2020F	2021F	2022F
Revenue	910	1,030	1,078	1,129
EBITDA	511	547	567	590
Pre-tax Profit	473	548	568	590
Net Profit	391	454	470	488
Net Pft (Pre Ex.)	391	454	470	488
Net Pft Gth (Pre-ex) (%)	7.8	16.0	3.6	3.8
EPS (S cts)	36.4	42.3	43.8	45.5
EPS Pre Ex. (S cts)	36.4	42.3	43.8	45.5
EPS Gth Pre Ex (%)	8	16	4	4
Diluted EPS (S cts)	36.4	42.3	43.8	45.5
Net DPS (S cts)	37.5	30.0	30.0	30.0
BV Per Share (S cts)	102	114	128	143
PE (X)	26.5	22.8	22.0	21.2
PE Pre Ex. (X)	26.5	22.8	22.0	21.2
P/Cash Flow (X)	24.8	21.2	21.1	20.3
EV/EBITDA (X)	19.0	17.5	16.6	15.8
Net Div Yield (%)	3.9	3.1	3.1	3.1
P/Book Value (X)	9.5	8.5	7.6	6.7
Net Debt/Equity (X)	CASH	CASH	CASH	CASH
ROAE (%)	35.8	39.2	36.2	33.6
Earnings Rev (%):		10	5	
Consensus EPS (S cts):		42.8	42.5	43.1
Other Broker Recs:		B: 3	S: 4	H: 8

Source of all data on this page: Company, DBS Bank, Bloomberg Finance L.P

24 Apr 2020

Medium-term outlook remains intact

Valuations getting rich, downgrade to HOLD with revised TP of **\$\$10.** We downgrade SGX to HOLD, with revised TP of \$\$10 on rich near-term valuations. We believe the share price should continue to be supported near its current levels by its absolute dividend of 30 Scts/year, implying c.3% yield at the current level, amid a lower-vielding market environment. SGX is targeting to double revenue from Data, Connectivity and Indices (DCI), as well as Fixed Income, Currencies, Commodities (FICC) segments in the next five years as it looks at various investment opportunities and bolt-on acquisitions to fuel growth. SGX announced its first bolt-on earnings-accretive acquisition of Scientific Beta, a smart beta index firm, as it targets growth in the DCI space. We believe SGX will continue to benefit from strong demand for risk management instruments in the medium term as it continues to execute growth strategies to build a multi-asset exchange.

Where we differ: SGX's volume growth in derivatives in the last few years is testament to its execution capabilities. We believe that SGX has the prerequisites to power growth in the identified segments of FICC and DCI in the medium term.

Potential catalysts: Higher-than-expected growth in securities daily average value (SDAV) is a near-term re-rating catalyst.

Valuation:

Downgrade to HOLD with revised TP of \$\$10 on rich near-term valuations. We downgrade SGX to HOLD on rich near-term valuations as its c.23x one-year forward PE multiple is at +1.5 SD above its 4-year historical mean. Our revised TP of \$\$10 is based on the dividend discount model (k=7%, g=4%, ROE=39%) as we revise our ROE assumptions from 38% to 39%. We also increased our earnings forecast for FY21F by c.5% as we believe that derivatives will continue to drive growth in revenues.

Key Risks to Our View:

Competition in derivatives business. SGX may see potential earnings downside should it face competition from HKEX which announced in March 2019 that it is planning to launch futures contracts. These may compete with SGX's FTSE China A50 Index Futures, which accounts for c.40% of SGX's total derivatives volume.

At A Glance

Issued Capital (m shrs)	1,070
Mkt. Cap (S\$m/US\$m)	10,315 / 7,245
Major Shareholders (%)	
SEL Holdings Pte Ltd	23.3
Temasek Holdings	5.7
Free Float (%)	71.o
3m Avg. Daily Val (US\$m)	32.3
GIC Industry: Financial / Diversified Financials	







WHAT'S NEW

Solid 3QFY20

SGX reported quarterly net profit of S\$138m (+38% y-o-y, +38% q-o-q) which was ahead of consensus. Total revenue growth (S\$296m, +29% y-o-y, +28% q-o-q) outpaced that of expenses as all segments saw strong growth in the quarter, driven by volatility in global markets and increased participation from customers. SGX's guidance for operating expenses increased to S\$485-495m on higher activity-related costs, launch of SGX care package (S\$5m) and acquisition of Scientific Beta. SGX will be incurring interest expense going forward on its c.S\$300m borrowings which will be rolled into long-term debt.

Strong volumes across all asset classes. Cash equities trading and clearing revenue improved 65% y-o-y/48% q-o-q as Securities Daily Average Value (SDAV) at S\$1.61bn rose 51% y-o-y and 57% q-o-q on stable average clearing fees of 2.79bps (prior year: 2.80bps). Derivatives revenues continued to be driven by volumes in the quarter as volumes grew 26% y-o-y/54% q-o-q as iron ore contracts, currency futures, and main equity index futures all saw a surge in volumes, while average fee per contract for Equity, Currency and Commodity derivatives was stable at S\$1.12 (prior year: S\$1.11). Total open interest remained high at US\$6bn (+5% y-o-y) with high margin balances driving derivatives' collateral management income. Going forward, given lower interest rates, we expect collateral management income growth to slow.

Product updates. SGX is looking into introducing Single Stock Futures for selected Singapore stocks, which will provide access to Singapore risk premium. In relation to discussions on the joint derivatives project at India's GIFT city with National Stock Exchange of India (NSE), it will likely see some delay due to the ongoing COVID-19 situation. SGX continues to look into scaling up in the FX and index space post Scientific Beta's acquisition, which has contributed S\$6m in revenue since Feb 2020.

Shift to half-yearly reporting from FY21; dividends continue to be paid quarterly. SGX will continue to pay a quarterly DPS of 7.5 Scts and management has reaffirmed its aim to pay a sustainable and growing dividend over time, in line with SGX's long-term growth prospects.

Valuation and recommendation

Downgrade to HOLD with revised TP of \$\$10 on rich near-term valuations. We downgrade SGX to HOLD, on rich near-term valuations as its c.23x one-year forward PE multiple is at +1.5 SD above its 4-year historical mean. Our revised TP of \$\$10 is based on the dividend discount model (k=7%, g=4%, ROE=39%) as we revise our ROE assumptions from 38% to 39%. We also increased our FY21F earnings forecast by c.5% as we believe that derivatives will continue to drive growth in revenues.

Quarterly / Interim Income Statement (S\$m)

FY Jun	3Q20	2Q20	3Q19	% chng q-o-q	% chng y-o-y
Fixed income, currencies and commodities	45.5	39.0	37.0	16.6%	23.0%
Equities	217.3	165.3	165.7	31.5%	31.1%
Data, connectivity and indicies	33.0	26.7	26.1	23.6%	26.5%
Total Revenue	295.8	230.9	228.8	28.1%	29.3%
Operating Expenses	-109.6	-89.4	-110.6	22.6%	-0.9%
Operating Profit	162.9	119.4	118.2	36.4%	37.8%
Pretax profit	165.7	121.3	121.2	36.6%	36.7%
Net Profit	137.5	99.0	99.7	38.9%	38.0%
Operating profit margin (%)	55.1%	51.7%	51.7%		
Net profit margin (%)	46.5%	42.9%	43.6%		
Securities daily average volume (m)	1,814	1,224	1,266	48.2%	43.3%
Securities daily average value (S\$m)	1,609	1,065	1,022	51.1%	57.4%
Derivatives average daily trading volume (m)	1.288	0.838	1.025	53.7%	25.6%
Velocity (%)	57%	34%	36%		
Open interest (m)	6.256	5.783	5.952		

Source of all data: Company, DBS Bank



CRITICAL DATA POINTS TO WATCH Critical Factors

Market activity

1) Securities


SGX derived about 20% of its total revenue from the Securities segment in FY19, down from 46% in FY10. Average daily turnover value (SDAV) for this segment has been hovering slightly above the S\$1bn mark in the last few years, from c.S\$1.5bn in FY10. SGX has already implemented several initiatives to boost liquidity in the securities market, including Market Maker and Liquidity Provider (MM/LP) programmes and new offerings such as Daily Leverage Certificates (DLCs) offered in July 2017. More recently, DLCs with higher leverage were also introduced. Other measures in the pipeline include: 1) Shorter settlement cycle to reduce credit risk exposure to the settlement system and improve efficiency, and 2) Short position reporting requirements to improve transparency. We note that SDAV has been a critical factor driving SGX's share price.

2) Derivatives

More product offerings. Contribution to total revenue from the Derivatives segment increased from about 21% in FY10 to c.51% in FY19. The mainly institutional-driven Derivatives business has been the key growth driver in recent years; derivatives revenue had overtaken the Securities market since 1QFY15. We expect this trend to persist as SGX continues to introduce more derivatives products, such as growing the market for currency futures. In FY19, SGX also benefitted from higher open interest and margin balances, in part due to higher interest rates which drove derivatives' collateral management income.

Diversifying business mix. SGX is also looking to diversify into other areas and reduce its reliance on the derivatives business by a) developing into a regional fixed income platform, with the launch of its bond trading platform – SGX Bond Pro; and b) growing its market data and index businesses.


M&A to drive earnings. The acquisition of the Baltic Exchange for £77.6m (S\$137m) in cash was completed at the end of 2016. This purchase should enable SGX to boost its plans to diversify revenue streams from the Securities market and reduce reliance on the Derivatives market. SGX is also looking to expand its global presence in shipping and has been developing Asian pricing benchmarks for commodities such as iron ore, liquefied natural gas and coking coal. In FY20, SGX announced the acquisition of Scientific Beta for EUR186m; Scientific Beta will be earnings accretive with annual revenues of c. EUR20m historically.







Appendix 1: A look at Company's listed history – what drives its share price?




SGX's share price has generally been tracking in the same direction with the STI Index. Correlation between SGX's share price and STI has weakened tremendously, as derivatives business continues to drive SGX's performance.

SGX share price vs average trading value for the market



SGX's share price and trading value for the market are more closely related, with correlation coefficient of ~0.8 from January 2001 till today. As at FY19, the Securities segment accounted for 20% of total revenue.

Total derivatives volume



Source: DBS Bank, Bloomberg Finance L.P.

Derivatives volume has been growing at a 5-year CAGR of 15%. In terms of contribution to the group's revenues, this had increased from c.30% in FY14 to c.51% in FY19.



Balance Sheet:

Cash and liquid assets account for almost half of the total assets as SGX needs to set aside at least S\$500m for working capital requirements. SGX expects to maintain healthy cash flows going forward. In FY18, SGX announced its new dividend policy of an absolute dividend of 7.5 Scts per quarter (dividends are paid on a quarterly basis).

Share Price Drivers:

New derivatives products to drive growth but gestation period may be long. The addition of new products should continue to drive growth for the Derivatives segment. Some of the new products include the NTR (net total return) Index futures launched in June 2017 and the MSCI China Index contracts launched in May 2016. However, some products may take a while before volumes pick up. The FTSE China A50 Index futures, which is the top index futures in terms of volume and accounts for about 40% of total volume for index futures in CY19, took about three years before seeing a rampup in volume.

Key Risks:

Competition in derivatives business. The top four index futures – FTSE China A50, Nikkei 225, SGX CNX Nifty and MSCI Taiwan – accounted for about c.70% of the total monthly volume in the derivatives market for CY19. SGX may face competition from HKEX which announced in March 2019 that it is planning to launch futures contracts which may compete with SGX's FTSE China A50 Index futures, its top index futures.


Sustainability of market liquidity. SGX's earnings are reliant on market volumes and capital market activities, which are sentiment-driven and influenced by the direction of foreign fund flows. Negative market sentiment resulting in lower liquidity could dampen market volumes and values.


Environment, Social, Governance:


SGX's ESG disclosure score had improved over the last few years to reach 26.0 (FY18), as SGX continues to improve its sustainable practices and advocates transparency and accountability as part of its sustainability agenda. SGX remains as a constituent stock of major sustainability indices.


Company Background

Singapore Exchange Limited (SGX) owns and operates Singapore's Securities and Derivatives Exchange and related clearing houses. The company also provides ancillary securities processing and information technology services to participants in the financial sector.













Key Assumptions

FY Jun	2018A	2019A	2020F	2021F	2022F
Average Daily Value (S\$m)	1,256	1,042	1,250	1,263	1,288

Income Statement (S\$m)

FY Jun	2018A	2019A	2020F	2021F	2022F
Revenue	845	910	1,030	1,078	1,129
Cost of Goods Sold	(420)	(449)	(489)	(516)	(546)
Gross Profit	425	461	542	562	584
Other Opng (Exp)/Inc	0.0	0.0	0.0	0.0	0.0
Operating Profit	425	461	542	562	584
Other Non Opg (Exp)/Inc	0.0	0.0	0.0	0.0	0.0
Associates & JV Inc	1.27	(1.5)	(5.0)	(5.0)	(5.0)
Net Interest (Exp)/Inc	10.9	13.5	11.0	11.0	11.0
Exceptional Gain/(Loss)	0.44	(0.1)	0.0	0.0	0.0
Pre-tax Profit	437	473	548	568	590
Tax	(74.3)	(81.9)	(93.7)	(97.9)	(102)
Minority Interest	0.0	0.0	0.0	0.0	0.0
Preference Dividend	0.0	0.0	0.0	0.0	0.0
Net Profit	363	391	454	470	488
Net Profit before Except.	363	391	454	470	488
EBITDA	476	511	547	567	590
Growth					
Revenue Gth (%)	5.5	7.7	13.2	4.6	4.8
EBITDA Gth (%)	5.6	7.2	7.0	3.8	3.9
Opg Profit Gth (%)	5.7	8.5	17.5	3.7	3.9
Net Profit Gth (Pre-ex) (%)	5.5	7.8	16.0	3.6	3.8
Margins & Ratio					
Gross Margins (%)	50.3	50.7	52.6	52.1	51.7
Opg Profit Margin (%)	50.3	50.7	52.6	52.1	51.7
Net Profit Margin (%)	43.0	43.0	44.0	43.6	43.2
ROAE (%)	34.1	35.8	39.2	36.2	33.6
ROA (%)	17.5	18.4	18.9	16.9	16.3
ROCE (%)	32.1	33.7	33.6	28.8	27.3
Div Payout Ratio (%)	88.4	102.9	71.0	68.5	66.0
Net Interest Cover (x)	NM	NM	NM	NM	NM

SGX's guidance for operating expenses increased to S\$485-495m on higher activityrelated costs, launch of SGX care package (S\$5m) and acquisition of Scientific Beta

Losses expected for SGX's portfolio of companies

FY Jun



3Q2020

2Q2020

Quarterly / Interim	Income Statement	(S\$m)
FY Jun	3Q2019	40

Revenue	229	248	248	231	296
Cost of Goods Sold	(111)	(125)	(113)	(112)	(133)
Gross Profit	118	123	135	119	163
Other Oper. (Exp)/Inc	0.0	0.0	0.0	0.0	0.0
Operating Profit	118	123	135 4.58	119	163
Other Non Opg (Exp)/Inc Associates & JV Inc	3.05 (0.6)	3.31 (0.3)	(0.5)	1.91 (0.8)	5.26 (2.4)
Net Interest (Exp)/Inc	0.0	0.0	0.0	0.0	0.0
• • •	0.0	0.0	0.0	0.0	0.0
Exceptional Gain/(Loss)	121	126	139	121	166
Pre-tax Profit Tax	(21.0)	(22.0)	(24.6)	(21.5)	(28.2)
Minority Interest	0.0	0.0	0.0	0.0	0.0
Net Profit	99.7	104	114	99.0	138
Net profit bef Except.	9 9.7 99.7	104	11 4 114	99.0 99.0	138
EBITDA	121	126	139	121	166
LUITUA	121	120	133	121	100
Growth					
Revenue Gth (%)	2.1	8.4	(0.2)	(6.7)	28.1
EBITDA Gth (%)	3.5	4.3	10.3	(13.2)	37.5
Opg Profit Gth (%)	4.0	3.9	9.7	(11.4)	36.4
Net Profit Gth (Pre-ex) (%) Margins	3.3	4.2	10.0	(13.3)	38.9
Gross Margins (%)	51.7	49.5	54.4	51.7	55.1
Opg Profit Margins (%)	51.7	49.5	54.4	51.7	55.1
Net Profit Margins (%)	43.6	49.5	46.1	42.9	46.5
3	45.0	41.3	40.1	42.3	40.5
Balance Sheet (S\$m)					
<u>FY Jun</u>	2018A	2019A	2020F	2021F	2022F
Net Fixed Assets	71.8	61.0	98.2	135	171
Invts in Associates & JVs	8.63	79.1	74.1	69.1	64.1
Other LT Assets	354	415	415	415	415
Cash & ST Invts	832	667	1,064	1,186	1,326
Inventory	0.0	0.0	0.0	0.0	0.0
Debtors	827	885	1,003	1,049	1,099
Other Current Assets	22.0	25.0	, 25.0	, 25.0	, 25.0
Total Assets	2,115	2,132	2,679	2,879	3,100
_		-		-	
ST Debt	0.0	0.0	278	278	278
Creditor	891	912	1,032	1,080	1,131
Other Current Liab	95.4	90.0	107	111	114
LT Debt	0.0	0.0	0.0	0.0	0.0
Other LT Liabilities	32.7	40.0	40.0	40.0	40.0
Shareholder's Equity	1,096	1,091	1,223	1,370	1,536
Minority Interests	0.0	0.0	0.0	0.0	0.0
Total Cap. & Liab.	2,115	2,132	2,679	2,879	3,100
Non-Cash Wkg. Capital	(137)	(91.0)	(111)	(116)	(122)
Net Cash/(Debt)	832	667	786	908	1,048
Debtors Turn (avg days)	354.7	343.5	334.5	347.4	347.2
Creditors Turn (avg days)	880.0	827.4	741.2	762.5	754.8
Inventory Turn (avg days)	N/A	N/A	N/A	N/A	N/A
Asset Turnover (x)	0.4	0.4	0.4	0.4	0.4
Current Ratio (x)	1.7	1.6	1.5	1.5	1.6
Quick Ratio (x)	1.7	1.5	1.5	1.5	1.6
Net Debt/Equity (X)	CASH	CASH	CASH	CASH	CASH
Net Debt/Equity ex MI (X)	CASH	CASH	CASH	CASH	CASH
Capex to Debt (%)	N/A	N/A	17.0	17.0	17.0
Z-Score (X)	7.5	7.4	7.1	7.0	7.0
					,

4Q2019

1Q2020






Cash Flow Statement (S\$m)

FY Jun	2018A	2019A	2020F	2021F	2022F
D T D £:+	427	470	F 40	FC0	F00
Pre-Tax Profit	437	473	548	568	590
Dep. & Amort.	50.2	51.3	10.1	10.6	11.0
Tax Paid	(71.4)	(82.4)	(77.2)	(93.7)	(97.9)
Assoc. & JV Inc/(loss)	(1.3)	1.50	5.00	5.00	5.00
Chg in Wkg.Cap.	(31.1)	(40.9)	3.45	1.36	1.47
Other Operating CF	42.9	15.1	0.0	0.0	0.0
Net Operating CF	427	417	489	491	509
Capital Exp.(net)	(78.5)	(47.4)	(47.4)	(47.4)	(47.4)
Other Invts.(net)	(25.5)	0.0	0.0	0.0	0.0
Invts in Assoc. & JV	(1.5)	(71.7)	0.0	0.0	0.0
Div from Assoc & JV	4.94	0.0	0.0	0.0	0.0
Other Investing CF	11.0	(41.2)	0.0	0.0	0.0
Net Investing CF	(89.5)	(160)	(47.4)	(47.4)	(47.4)
Div Paid	(300)	(401)	(322)	(322)	(322)
Chg in Gross Debt	0.0	0.0	278	0.0	0.0
Capital Issues	0.0	0.0	0.0	0.0	0.0
Other Financing CF	(2.3)	(20.7)	0.0	0.0	0.0
Net Financing CF	(302)	(422)	(44.0)	(322)	(322)
Currency Adjustments	0.01	0.0	0.0	0.0	0.0
Chg in Cash	35.2	(165)	398	122	140
Opg CFPS (S cts)	42.7	42.7	45.2	45.6	47.3
Free CFPS (S cts)	32.5	34.5	41.1	41.3	43.0

Technology-related capex guidance of S\$45-50m

Source: Company, DBS Bank

Target Price & Ratings History



S.No.	Date of Report	Closing Price	12-mth Target Price	Rating
1:	26 Apr 19	7.40	7.05	HOLD
2:	27 Jun 19	7.95	7.05	HOLD
3:	01 Aug 19	7.78	8.30	BUY
4:	03 Aug 19	7.98	8.30	BUY
5:	07 Aug 19	8.02	8.30	BUY
6:	25 Oct 19	8.85	8.90	BUY
7:	12 Jan 20	8.79	8.90	BUY
8:	24 Jan 20	8.81	9.60	BUY

Note: Share price and Target price are adjusted for corporate actions.

Source: DBS Bank Analyst: Rui Wen LIM



DBS Bank recommendations are based on an Absolute Total Return* Rating system, defined as follows:

STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)

BUY (>15% total return over the next 12 months for small caps, >10% for large caps)

HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)

FULLY VALUED (negative total return, i.e., > -10% over the next 12 months)

SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

*Share price appreciation + dividends

Completed Date: 24 Apr 2020 19:10:55 (SGT)
Dissemination Date: 24 Apr 2020 19:40:00 (SGT)

Sources for all charts and tables are DBS Bank unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by DBS Bank Ltd. This report is solely intended for the clients of DBS Bank Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.



Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests² in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

- 1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or their subsidiaries and/or other affiliates have a proprietary position in Singapore Exchange recommended in this report as of 31 Mar 2020.
- 2. Neither DBS Bank Ltd nor DBS HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

Compensation for investment banking services:

3. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Directorship/trustee interests:

4. Sok Hui CHNG, a member of DBS Group Management Committee, is a Director of Singapore Exchange as of 01 Apr 2020. Tham Sai Choy, a member of DBS Group Holdings Board of Directors, is a Chairman of Singapore Exchange Listings Advisory Committee as of 31 Mar 2020.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.



Disclosure of previous investment recommendation produced:

5. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

RESTRICTIONS ON DISTRIBUTION

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is being distributed in Australia by DBS Bank Ltd, DBSVS or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946.
	DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS Bank Ltd and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws.
	Distribution of this report is intended only for "wholesale investors" within the meaning of the CA.
Hong Kong	This report has been prepared by a person(s) who is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities in Hong Kong pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Bank (Hong Kong) Limited, a registered institution registered with the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore.
	For any query regarding the materials herein, please contact Carol Wu (Reg No. AH8283) at dbsvhk@dbs.com
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies.
	Wong Ming Tek, Executive Director, ADBSR





Other jurisdictions	referred to herein should contact DBSVUSA directly and not its affiliate. In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.
United States	This report was prepared by DBS Bank Ltd. DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608 - 610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
	In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
United Kingdom	This report is produced by DBS Bank Ltd which is regulated by the Monetary Authority of Singapore. This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.



DBS Regional Research Offices

HONG KONG DBS (Hong Kong) Ltd

Contact: Carol Wu
13th Floor One Island East,
18 Westlands Road,
Quarry Bay, Hong Kong
Tel: 852 3668 4181
Fax: 852 2521 1812
e-mail: dbsvhk@dbs.com

THAILAND

DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building, 9th, 14th-15th Floor Rama 1 Road, Pathumwan, Bangkok Thailand 10330 Tel. 66 2 857 7831

Fax: 66 2 658 1269 e-mail: research@th.dbs.com Company Regn. No 0105539127012

Securities and Exchange Commission, Thailand

MALAYSIA

AllianceDBS Research Sdn Bhd

Contact: Wong Ming Tek (128540 U) 19th Floor, Menara Multi-Purpose, Capital Square, 8 Jalan Munshi Abdullah 50100 Kuala Lumpur, Malaysia.

Tel.: 603 2604 3333 Fax: 603 2604 3921

e-mail: general@alliancedbs.com

INDONESIA

PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel: 62 21 3003 4900 Fax: 6221 3003 4943

e-mail: indonesiaresearch@dbs.com

SINGAPORE DBS Bank Ltd

Contact: Janice Chua 12 Marina Boulevard, Marina Bay Financial Centre Tower 3 Singapore 018982

Tel: 65 6878 8888 Fax: 65 65353 418

e-mail: equityresearch@dbs.com Company Regn. No. 196800306E